# 2026-00633: DEA Bans 4-Fluoroamphetamine as Schedule I Controlled Substance 2026-00633, Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-01-15, effective 2026-02-17 (as of 2026-06-11). - Canonical: https://policyrisk.com/federal-register/2026-00633 - As of: 2026-06-11 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2026-00633 - Title: Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I - Type: Rule - Agencies: Justice Department; Drug Enforcement Administration - Citation: 91 FR 1692 - Published: 2026-01-15 - Effective: 2026-02-17 - Comments close: not stated - Significant: no - Touches household money: no - Regulation identifier numbers: none - Last updated: 2026-06-11 ## In one line DEA Bans 4-Fluoroamphetamine as Schedule I Controlled Substance ## Summary Starting February 17, 2026, 4-fluoroamphetamine (4-FA) is officially a Schedule I drug, meaning it’s now tightly controlled like other dangerous substances. This change affects anyone who makes, sells, studies, or even possesses 4-FA, bringing serious legal rules and penalties. The move helps the U.S. follow international drug laws and keeps communities safer. ## Abstract With the issuance of this final rule, the Drug Enforcement Administration places 4-fluoroamphetamine (4-FA; 1-(4- fluorophenyl)propan-2-amine; para-fluoroamphetamine), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4-fluoroamphetamine. ## Effects PRIA read - 4‑FA Becomes Schedule I Drug: cost, high. Starting February 17, 2026, 4‑fluoroamphetamine (4‑FA) is placed in Schedule I of the Controlled Substances Act. Anyone who makes, distributes, imports, exports, possesses, or otherwise handles 4‑FA will be subject to the regulatory controls and administrative, civil, and criminal sanctions that ap… - DEA Registration Required to Handle 4‑FA: cost, medium. Anyone who handles (manufactures, distributes, reverse distributes, imports, exports, engages in research, conducts instructional activities or chemical analysis with, or possesses) 4‑FA must register with the Drug Enforcement Administration under 21 U.S.C. 822, 823, 957, and 958 and in accordance… - Research on 4‑FA Requires DEA Permission: cost, medium. Placement of 4‑FA in Schedule I does not ban research but requires those wishing to conduct research on 4‑FA to seek DEA permission and appropriate registration. The rule cites 21 U.S.C. provisions and provides a DEA webform for researchers to request authorization. - Surrender or Transfer Stocks Before Effective Date: cost, medium. If a person is unwilling or unable to obtain a Schedule I registration, they must surrender or transfer all quantities of 4‑FA to a DEA‑registered person before the effective date of February 17, 2026, and dispose of 4‑FA in accordance with 21 CFR part 1317 and other applicable laws. Retail sales o… - New Handling Controls: Security, Records, Inventories: cost, medium. As a Schedule I substance, 4‑FA is subject to Schedule I security requirements, labeling and packaging rules, manufacturing quotas, initial and biennial inventories (initial inventory on the date the registrant first handles controlled substances; inventory thereafter every two years), recordkeepin… ## Related documents - [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09 - [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20 - [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24 - [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19 - [2026-20749](https://policyrisk.com/federal-register/2026-20749): Vladimir Romaniv, P.A.; Decision and Order, 2026-10-09 - [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09 ## Sources - [2026-00633 on federalregister.gov](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) - [2026-00633 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-01-15/pdf/2026-00633.pdf) ## Related - [Previous: 2026-00628, Pyriofenone; Pesticide Tolerances](https://policyrisk.com/federal-register/2026-00628) - [Next: 2026-00653, Hazard Communication Standard](https://policyrisk.com/federal-register/2026-00653) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2026-00633 (as of 2026-06-11).